Abreu Y Abreu A T, Velarde-Ruiz Velasco J A, Zavala-Solares M R, Remes-Troche J M, Carmona-Sánchez R I, Aldana-Ledesma J M, Camacho-Ortiz A, Contreras-Omaña R, Díaz-Seoane R, Elizondo-Vázquez C T, Garza-González E, Grajales-Figueroa G, Gómez-Escudero O, Jacobo-Karam J S, Morales-Arámbula M, Olivares-Guzmán L O, Sifuentes-Osornio J, Siu-Moguel A G, Soto-Solís R, Valdovinos-García L R, Valdovinos-Díaz M A, Vázquez-Elizondo G, Lazo-de la Vega Jasso S A
Hospital Ángeles de Pedregal, Ciudad de México, México.
Servicio de Gastroenterología, Hospital Civil de Guadalajara «Fray Antonio Alcalde», Guadalajara, Jalisco, México.
Rev Gastroenterol Mex (Engl Ed). 2019 Apr-Jun;84(2):204-219. doi: 10.1016/j.rgmx.2018.12.001. Epub 2019 Apr 12.
In recent decades, Clostridium difficile infection (CDI) has become a worldwide health problem. Mexico is no exception, and therefore the Asociación Mexicana de Gastroenterología brought together a multidisciplinary group (gastroenterologists, endoscopists, internists, infectious disease specialists, and microbiologists) to carry out the "Consensus on the prevention, diagnosis, and treatment of Clostridium difficile infection", establishing useful recommendations (in relation to the adult population) for the medical community. Said recommendations are presented herein. Among them, it was recognized that CDI should be suspected in subjects with diarrhea that have a history of antibiotic and/or immunosuppressant use, but that it can also be a community-acquired infection. A 2-step diagnostic algorithm was proposed, in which a highly sensitive test, such as glutamate dehydrogenase (GDH), is first utilized, and if positive, confirmed by the detection of toxins through immunoassay or nucleic acid detection tests. Another recommendation was that CDI based on clinical evaluation be categorized as mild-moderate, severe, and complicated severe, given that such a classification enables better therapeutic decisions to be made. In mild-moderate CDI, oral vancomycin is the medication of choice, and metronidazole is recommended as an alternative treatment. In addition, fecal microbiota transplantation was recognized as an efficacious option in patients with recurrence or in the more severe cases of infection, and surgery should be reserved for patients with severe colitis (toxic megacolon), in whom all medical treatment has failed.
近几十年来,艰难梭菌感染(CDI)已成为一个全球性的健康问题。墨西哥也不例外,因此墨西哥胃肠病学协会召集了一个多学科小组(胃肠病学家、内镜医师、内科医生、传染病专家和微生物学家),开展了“艰难梭菌感染预防、诊断和治疗共识”,为医学界制定了(针对成年人群体的)有用建议。本文介绍了这些建议。其中,人们认识到,对于有抗生素和/或免疫抑制剂使用史且腹泻的患者应怀疑患有CDI,但它也可能是社区获得性感染。提出了一种两步诊断算法,首先使用高灵敏度检测方法,如谷氨酸脱氢酶(GDH),如果检测结果为阳性,则通过免疫测定或核酸检测试验检测毒素来进行确认。另一条建议是,基于临床评估将CDI分为轻度-中度、重度和复杂性重度,因为这种分类有助于做出更好的治疗决策。在轻度-中度CDI中,口服万古霉素是首选药物,甲硝唑被推荐作为替代治疗。此外,粪便微生物群移植被认为是复发性患者或感染较严重病例的有效选择,对于所有药物治疗均失败的重症结肠炎(中毒性巨结肠)患者应考虑手术治疗。